

Mohammad Shadab Siddiqui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1145468/publications.pdf>

Version: 2024-02-01

72
papers

3,389
citations

201385

27
h-index

155451

55
g-index

73
all docs

73
docs citations

73
times ranked

4078
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 45-54.e6. | 2.4 | 29 |
| 2 | An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 619-629.e7. | 2.4 | 90 |
| 3 | Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 445-455.e2. | 2.4 | 13 |
| 4 | Interplay Between Dyslipidemia, Atherogenic Lipoproteins, and Residual Atherogenic Risk in Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1660-1662.e1. | 2.4 | 2 |
| 5 | A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2462-2473.e10. | 2.4 | 59 |
| 6 | Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. <i>Endocrine Practice</i> , 2022, 28, 223-230. | 1.1 | 31 |
| 7 | A Meta-Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients. <i>Liver Transplantation</i> , 2022, 28, 689-699. | 1.3 | 15 |
| 8 | A Diagnostic Test Meta-Analysis Evaluating Imaging-Based and Blood Biomarker-Based Assessment Tools for Fibrosis After Liver Transplantation. <i>Liver Transplantation</i> , 2022, 28, 659-669. | 1.3 | 6 |
| 9 | Early laboratory values after liver transplantation are associated with anastomotic biliary strictures. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2022, 26, 76-83. | 0.1 | 2 |
| 10 | Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 483-484. | 1.9 | 1 |
| 11 | Differential fuel utilization in liver transplant recipients and its relationship with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1401-1409. | 1.9 | 8 |
| 12 | Glomerular filtration rate early after liver transplantation independently predicts atherosclerotic events. <i>Liver Transplantation</i> , 2022, 28, 1186-1195. | 1.3 | 4 |
| 13 | Performance of Vibration-Controlled Transient Elastography and Clinical Prediction Models In Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , . | 2.4 | 1 |
| 14 | Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 483-496. | 4.5 | 49 |
| 15 | Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1076-1087. | 1.9 | 15 |
| 16 | Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. <i>Hepatology International</i> , 2022, 16, 269-281. | 1.9 | 23 |
| 17 | Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12,620,736 Individuals. <i>Endocrine Practice</i> , 2022, 28, 667-672. | 1.1 | 34 |
| 18 | Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 521-530. | 5.1 | 116 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | A systematic review and meta-analysis on the impact of pre-existing and new-onset atrial fibrillation on outcomes before and after liver transplantation. <i>Digestive and Liver Disease</i> , 2022, 54, 614-621. | 0.4 | 11 |
| 20 | Validation of the accuracy of the FASTâ„¢ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. <i>PLoS ONE</i> , 2022, 17, e0266859. | 1.1 | 20 |
| 21 | Sex Differences in Vascular Endothelial Function After Liver Transplant. <i>FASEB Journal</i> , 2022, 36, . | 0.2 | 0 |
| 22 | Weight Gain, Fibroblast Growth Factorâ„¢23, and Vascular Function in Liver Transplant Recipients. <i>FASEB Journal</i> , 2022, 36, . | 0.2 | 0 |
| 23 | Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2202-2204. | 2.4 | 7 |
| 24 | A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2670-2672. | 2.4 | 41 |
| 25 | Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu. <i>Digestive Diseases and Sciences</i> , 2021, 66, 263-272. | 1.1 | 11 |
| 26 | Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 367-374. | 2.4 | 33 |
| 27 | Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications. <i>Liver Transplantation</i> , 2021, 27, 1326-1333. | 1.3 | 6 |
| 28 | A metaâ„¢analysis of the cumulative incidence, risk factors, and clinical outcomes associated with chronic kidney disease after liver transplantation. <i>Transplant International</i> , 2021, 34, 2524-2533. | 0.8 | 6 |
| 29 | Office-Based Weight Loss Counseling Is Ineffective in Liver Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2020, 65, 639-646. | 1.1 | 9 |
| 30 | Reply. <i>Hepatology</i> , 2020, 71, 401-402. | 3.6 | 0 |
| 31 | Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2020, 72, 25-33. | 1.8 | 88 |
| 32 | Clopidogrel Responsiveness in Patients With Decompensated Cirrhosis of the Liver Undergoing Pre-Transplant PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 661-663. | 1.1 | 7 |
| 33 | The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00127. | 1.0 | 15 |
| 34 | Harnessing Muscleâ„¢Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2020, 11, 592373. | 1.5 | 42 |
| 35 | Review article: the impact of liverâ„¢directed therapies on the atherogenic risk profile in nonâ„¢alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 619-636. | 1.9 | 6 |
| 36 | Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2020, 49, xiii-xiv. | 1.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 165-178. | 1.0 | 3 |
| 38 | The Impact of Coronary Artery Disease and Statins on Survival After Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1514-1523. | 1.3 | 46 |
| 39 | Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 12541. | 1.6 | 106 |
| 40 | Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2019, 51, 1895-1901. | 0.3 | 6 |
| 41 | Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients. <i>Hepatology</i> , 2019, 70, 98-107. | 3.6 | 29 |
| 42 | Prevalence and Severity of Nonalcoholic Fatty Liver Disease Among Caregivers of Patients With Nonalcoholic Fatty Liver Disease Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2132-2133. | 2.4 | 12 |
| 43 | <p>Obesity paradox in cardiovascular disease: where do we stand?</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 89-100. | 1.0 | 234 |
| 44 | Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. <i>Hepatology</i> , 2019, 70, 1690-1703. | 3.6 | 196 |
| 45 | Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1877-1885.e5. | 2.4 | 145 |
| 46 | Editorial: ascitic cholesterol is it superior to serum ascites albumin gradient?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 814-815. | 1.9 | 1 |
| 47 | The relationship between coronary artery disease and cardiovascular events early after liver transplantation. <i>Liver International</i> , 2019, 39, 1363-1371. | 1.9 | 30 |
| 48 | The Relationship Between Hypoadiponectinemia and Cardiovascular Events in Liver Transplant Recipients. <i>Transplantation</i> , 2019, 103, 2323-2328. | 0.5 | 12 |
| 49 | Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. <i>Drugs</i> , 2019, 79, 75-84. | 4.9 | 17 |
| 50 | Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS0200) on Weight and Metabolic Parameters. <i>Obesity</i> , 2019, 27, 59-67. | 1.5 | 18 |
| 51 | Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 156-163.e2. | 2.4 | 322 |
| 52 | The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease. <i>Hepatology</i> , 2019, 69, 1372-1374. | 3.6 | 14 |
| 53 | Relation of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease to Left Ventricular Diastolic Function and Exercise Tolerance. <i>American Journal of Cardiology</i> , 2019, 123, 466-473. | 0.7 | 36 |
| 54 | Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis. <i>JCI Insight</i> , 2019, 4, . | 2.3 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Adherence to Recommended Inpatient Hepatic Encephalopathy Workup. <i>Journal of Hospital Medicine</i> , 2019, 14, 157-160. | 0.7 | 15 |
| 56 | Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation. <i>Liver Transplantation</i> , 2018, 24, 872-880. | 1.3 | 43 |
| 57 | Reply. <i>Liver Transplantation</i> , 2018, 24, 978-979. | 1.3 | 0 |
| 58 | Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. <i>Liver Transplantation</i> , 2018, 24, 333-342. | 1.3 | 78 |
| 59 | Treatment of HCV in the Department of Corrections in the Era of Oral Medications. <i>Journal of Correctional Health Care</i> , 2018, 24, 127-136. | 0.2 | 29 |
| 60 | The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. <i>Hepatology</i> , 2018, 67, 534-548. | 3.6 | 266 |
| 61 | Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012. | 3.6 | 125 |
| 62 | Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2018, 67, 134-144. | 3.6 | 192 |
| 63 | Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1177-1186. | 0.2 | 98 |
| 64 | Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease. <i>Thrombosis Research</i> , 2017, 150, 41-43. | 0.8 | 5 |
| 65 | Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis. <i>Transplantation</i> , 2017, 101, 1867-1874. | 0.5 | 112 |
| 66 | Endoscopic Cyanoacrylate Injection with Post-injection Audible Doppler Assessment of Gastric Varices: A Single-Institution Experience. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3091-3099. | 1.1 | 3 |
| 67 | Non-alcoholic Fatty Liver Disease in Non-obese Patients. <i>Current Hepatology Reports</i> , 2017, 16, 382-390. | 0.4 | 0 |
| 68 | Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 572-579. | 1.9 | 38 |
| 69 | Preserved hemostatic status in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 65, 980-987. | 1.8 | 72 |
| 70 | The etiology of cirrhosis is a strong determinant of brain reserve: A multimodal magnetic resonance imaging study. <i>Liver Transplantation</i> , 2015, 21, 1123-1132. | 1.3 | 45 |
| 71 | Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (β^2 -Cell) Function. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2529-2537. | 1.1 | 28 |
| 72 | Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1000-1008.e3. | 2.4 | 164 |